AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3720724 — intervention group
Group type: COMPARATOR
Intervention: Carrying 0% of body mass in an external frame backpack
Number of subjects: 10
Study 3720724 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying 20% of body mass in an external frame backpack
Number of subjects: 10
Study 3720724 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying 40% of body mass in an external frame backpack
Number of subjects: 10
Study 3720724 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 0.75 stature per second
Number of subjects: 10
Study 3720724 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 0.95 stature per second
Number of subjects: 10
Study 30504456 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Valsalva manoeuvre (VM)
Number of subjects: 75
Study 30504456 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva Assist Device (VAD)
Number of subjects: 75
Study 30504456 — intervention group
Group type: COMPARATOR
Intervention: Supine Valsalva manoeuvre (VM)
Number of subjects: 75
Study 30504456 — intervention group
Group type: COMPARATOR
Intervention: Manometer
Number of subjects: 75
Study 27659116 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (SCP, n=8)
Number of subjects: 16
Study 27659116 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback control training (electromyogram feedback, n=8)
Number of subjects: 16
Study 27659116 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful learners (n=9)
Number of subjects: 16
Study 26894628 — intervention group
Group type: EXPERIMENTAL
Intervention: EWA‐LOR
Number of subjects: 100
Study 26894628 — intervention group
Group type: COMPARATOR
Intervention: Conventional LOR
Number of subjects: 100
Study 25494343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational program
Number of subjects: 306
Study 25494343 — intervention group
Group type: COMPARATOR
Intervention: Common cardiac rehabilitation
Number of subjects: 306
Study 25494343 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment proposals participation
Number of subjects: 306
Study 21850019 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 0
Study 21850019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20460063 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius recession surgery
Number of subjects: 4
Study 20460063 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 4
Study 18669426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 2.5 mg of cyclosporine per kilogram of body weight
Number of subjects: 58
Study 18669426 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 58
Study 16320283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical as-treated model
Number of subjects: 0
Study 16320283 — intervention group
Group type: COMPARATOR
Intervention: Mixed effects models
Number of subjects: 0
Study 12743240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 227
Study 12743240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 12541430 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alerting tasks (maths calculation, answering questions)
Number of subjects: 40
Study 12541430 — intervention group
Group type: COMPARATOR
Intervention: Passive alerting tasks (listening to music, listening to stories)
Number of subjects: 40
Study 9485968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml hyperbaric 0.5% bupivacaine
Number of subjects: 54
Study 9485968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml hyperbaric 0.5% bupivacaine
Number of subjects: 54
Study 8339699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-age child care group
Number of subjects: 59
Study 8339699 — intervention group
Group type: COMPARATOR
Intervention: Same-age child care group
Number of subjects: 59
Study 2422463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (3 doses of 20 mg given sublingually at 8‐h intervals)
Number of subjects: 12
Study 2422463 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 28662370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher calorie exposure (kcal/kg) received from ICU days 1-6
Number of subjects: 298
Study 28662370 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie exposure (kcal/kg) received after ICU day 7
Number of subjects: 298
Study 27312405 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 23
Study 27312405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24627629 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 20
Study 24627629 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Number of subjects: 20
Study 24627629 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 20
Study 23292820 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) supermarket (VMall) treatment, 10 sessions of 45 minutes each.
Number of subjects: 12
Study 23292820 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy (OT) cognitive retraining without VR, 10 sessions.
Number of subjects: 12
Study 20303641 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN Excisor
Number of subjects: 420
Study 20303641 — intervention group
Group type: COMPARATOR
Intervention: LLETZ
Number of subjects: 420
Study 20303641 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN Excisor for CIN 1
Number of subjects: 420
Study 20303641 — intervention group
Group type: COMPARATOR
Intervention: LLETZ for CIN 1
Number of subjects: 420
Study 20303641 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN Excisor for CIN 2
Number of subjects: 420
Study 20303641 — intervention group
Group type: COMPARATOR
Intervention: LLETZ for CIN 2
Number of subjects: 420
Study 20303641 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN Excisor for CIN 3
Number of subjects: 420
Study 20303641 — intervention group
Group type: COMPARATOR
Intervention: LLETZ for CIN 3
Number of subjects: 420
Study 19139601 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict treatment to maintain systolic blood pressure below 140 mmHg
Number of subjects: 4418
Study 19139601 — intervention group
Group type: COMPARATOR
Intervention: Mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg
Number of subjects: 4418
Study 16765550 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC method for all‐trans‐retinol
Number of subjects: 2
Study 16765550 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC method for alpha‐tocopherol
Number of subjects: 2
Study 16765550 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC method for coenzyme Q(10)
Number of subjects: 2
Study 12860343 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis (I or II rAFS stage)
Number of subjects: 50
Study 12860343 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis (III or IV rAFS stage)
Number of subjects: 50
Study 12860343 — intervention group
Group type: COMPARATOR
Intervention: Follicular ovarian cysts
Number of subjects: 50
Study 12860343 — intervention group
Group type: COMPARATOR
Intervention: Dermoid tumors of ovaries
Number of subjects: 50
Study 10967067 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (6 mg/kg over 5 minutes followed by 60 microg/kg per minute over 55 minutes)
Number of subjects: 12
Study 10967067 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg over 5 minutes followed by 30 microg/kg per minute over 55 minutes)
Number of subjects: 12
Study 8979626 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril monotherapy
Number of subjects: 53
Study 31165895 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-02
Number of subjects: 44
Study 31165895 — intervention group
Group type: COMPARATOR
Intervention: S-01 (sham control)
Number of subjects: 44
Study 30121686 — intervention group
Group type: EXPERIMENTAL
Intervention: Music guided deep breathing exercise
Number of subjects: 87
Study 30121686 — intervention group
Group type: COMPARATOR
Intervention: Listening to music (control)
Number of subjects: 87
Study 25619927 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP intervention
Number of subjects: 252
Study 24569127 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (ACD) at 0.5 μg/day (n = 14)
Number of subjects: 32
Study 24569127 — intervention group
Group type: COMPARATOR
Intervention: Maxacalcitol (OCT) (n = 13)
Number of subjects: 32
Study 24324554 — intervention group
Group type: EXPERIMENTAL
Intervention: Solving math problems
Number of subjects: 0
Study 24324554 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing semantic judgment task
Number of subjects: 0
Study 24324554 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (no additional task)
Number of subjects: 0
Study 20493364 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 degrees C saline irrigation
Number of subjects: 120
Study 20493364 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature (25 degrees C) saline irrigation
Number of subjects: 120
Study 18024209 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 24
Study 18024209 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 16479824 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women after menopause
Number of subjects: 45
Study 16479824 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women before menopause
Number of subjects: 45
Study 16479824 — intervention group
Group type: COMPARATOR
Intervention: Control group (women with normal BMI)
Number of subjects: 45
Study 11967633 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg CCK-8
Number of subjects: 13
Study 11967633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11967633 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 in healthy controls
Number of subjects: 13
Study 11967633 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8
Number of subjects: 13
Study 10416094 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 139
Study 10416094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 7575103 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol at low plasma level (2 ng/mL)
Number of subjects: 65
Study 7575103 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol at moderate plasma level (10 ng/mL)
Number of subjects: 65
Study 7575103 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol with subsequent lowering of plasma levels
Number of subjects: 65
Study 2075079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefuroxime 1,500 mg plus 500 mg metronidazole
Number of subjects: 396
Study 7353344 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin (15,000 U)
Number of subjects: 48
Study 7353344 — intervention group
Group type: COMPARATOR
Intervention: Sodium heparins (3 types)
Number of subjects: 48
Study 31088530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCEs)
Number of subjects: 4057
Study 27733466 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SF-12 mental component score
Number of subjects: 0
Study 27733466 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study 27733466 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen (BUN)
Number of subjects: 0
Study 27733466 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0
Study 27733466 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine level
Number of subjects: 0
Study 26377054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2776
Study 26377054 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2776
Study 26377054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776
Study 26377054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (women)
Number of subjects: 2776
Study 26377054 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes development
Number of subjects: 2776
Study 24084509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds consumed with breakfast (43 g/day)
Number of subjects: 137
Study 24084509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds consumed as a morning snack (43 g/day)
Number of subjects: 137
Study 24084509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds consumed as an afternoon snack (43 g/day)
Number of subjects: 137
Study 24084509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no almonds)
Number of subjects: 137
Study 24084509 — intervention group
Group type: EXPERIMENTAL
Intervention: All almond groups
Number of subjects: 137
Study 21317775 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (nine 2-hour sessions: 5 education sessions and 4 autogenic relaxation sessions)
Number of subjects: 216
Study 21317775 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 21317775 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 216
Study 19213769 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV + LTOT
Number of subjects: 144
Study 19213769 — intervention group
Group type: COMPARATOR
Intervention: LTOT alone
Number of subjects: 144
Study 17124017 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fetal pulse oximetry
Number of subjects: 5341
Study 17124017 — intervention group
Group type: COMPARATOR
Intervention: Masked fetal pulse oximetry
Number of subjects: 5341
Study 14977771 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment defined as binocular acuity of less than 6/18
Number of subjects: 1742
Study 14977771 — intervention group
Group type: EXPERIMENTAL
Intervention: Age related macular degeneration (AMD)
Number of subjects: 1742
Study 14977771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract
Number of subjects: 1742
Study 14977771 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 1742
Study 14977771 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic degeneration
Number of subjects: 1742
Study 14977771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic eye disease
Number of subjects: 1742
Study 11266478 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom‐made orthoses
Number of subjects: 255
Study 11266478 — intervention group
Group type: EXPERIMENTAL
Intervention: Over‐the‐counter arch supports
Number of subjects: 255
Study 11266478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension night splints
Number of subjects: 255
Study 11266478 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 255
Study 8996142 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin AUC of 4 (AUC4) and cyclophosphamide 500 mg/m2
Number of subjects: 222
Study 8996142 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 8 (AUC8) and cyclophosphamide 500 mg/m2
Number of subjects: 222
Study 8996142 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 8 (AUC8)
Number of subjects: 222
Study 8996142 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin AUC of 4 (AUC4)
Number of subjects: 222
Study 8512006 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (up to 200 mg/die intravenously)
Number of subjects: 25
Study 8512006 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 25
Study 3498402 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 3498402 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam-propanidid
Number of subjects: 40
Study 29522113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate, administered in 3 rounds over a 3-day course.
Number of subjects: 2268
Study 29522113 — intervention group
Group type: COMPARATOR
Intervention: Control villages (no MDA).
Number of subjects: 2268
Study 29522113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate.
Number of subjects: 2268
Study 28831390 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUACEL Ag Surgical dressing
Number of subjects: 240
Study 28831390 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 240
Study 26576633 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based intervention group
Number of subjects: 50
Study 26576633 — intervention group
Group type: COMPARATOR
Intervention: Control condition group (treatment as usual)
Number of subjects: 50
Study 22946700 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised goal-directed therapy targeting stroke volume and oxygen delivery
Number of subjects: 40
Study 22946700 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded central haemodynamic data)
Number of subjects: 40
Study 22403976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) mouthwash with 6% alcohol
Number of subjects: 0
Study 22403976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) alcohol-free mouthwash
Number of subjects: 0
Study 22403976 — intervention group
Group type: COMPARATOR
Intervention: Negative control mouthwash without CPC
Number of subjects: 0
Study 18512165 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) patches
Number of subjects: 783
Study 18512165 — intervention group
Group type: COMPARATOR
Intervention: Control group (stopping or continuing antihypertensive treatments)
Number of subjects: 783
Study 15778907 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (lidocaine 5% patch, IBSA)
Number of subjects: 18
Study 15778907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12419092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CsA
Number of subjects: 128
Study 12419092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% CsA
Number of subjects: 128
Study 12419092 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 128
Study 12419092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% CsA (post crossover)
Number of subjects: 128
Study 10614796 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial revascularization strategy
Number of subjects: 558
Study 10614796 — intervention group
Group type: COMPARATOR
Intervention: Initial medical care strategy
Number of subjects: 558
Study 10614796 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 558
Study 7577287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms kg‐1) with famotidine 20 mg
Number of subjects: 77
Study 7577287 — intervention group
Group type: COMPARATOR
Intervention: Control (famotidine 20 mg alone)
Number of subjects: 77
Study 1774006 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic local anesthesia (TLA) with lidocaine
Number of subjects: 76
Study 1774006 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 76
Study 6173480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide (Buscopan)
Number of subjects: 55
Study 6173480 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 55
Study 30967099 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 mg/kg oral racemic MDA
Number of subjects: 0
Study 30295429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab biosimilar GP2013
Number of subjects: 107
Study 30295429 — intervention group
Group type: COMPARATOR
Intervention: Reference RTX
Number of subjects: 107
Study 30295429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Short retention interval with forward prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Short retention interval with meal-name prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Short retention interval with open prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Short retention interval with reverse prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Long retention interval with forward prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Long retention interval with meal-name prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Long retention interval with open prompts
Number of subjects: 455
Study 28174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Long retention interval with reverse prompts
Number of subjects: 455
Study 25997508 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate cream (MAL)
Number of subjects: 30
Study 25997508 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA gel (BF-200 ALA)
Number of subjects: 30
Study 25997508 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT for basal cell carcinomas (BCCs)
Number of subjects: 30
Study 23408040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and carboplatin
Number of subjects: 40
Study 23408040 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine
Number of subjects: 40
Study 21741891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging (USI) during lifting and reaching tasks
Number of subjects: 20
Study 19567246 — intervention group
Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(7) cfu/ml
Number of subjects: 10
Study 19567246 — intervention group
Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(9) cfu/ml
Number of subjects: 10
Study 19567246 — intervention group
Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(5) cfu/ml
Number of subjects: 10
Study 19567246 — intervention group
Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SQ at 10(5) cfu/ml
Number of subjects: 10